Palivizumab in the prevention of respiratory syncytial virus disease

Expert Opinion on Biological Therapy

Volumn 2, Issue 7, 2002, Pages 763-769

  Krilov, Leonard R ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PALIVIZUMAB;

CONGENITAL HEART DISEASE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HIGH RISK POPULATION; IMMUNE DEFICIENCY; LOWER RESPIRATORY TRACT INFECTION; LUNG DISEASE; PREMATURITY; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RISK FACTOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; HUMANS; IMMUNIZATION, PASSIVE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 0036793328     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.7.763     Document Type: Review

References (61)

1. Collins PL, Mcintosh K, Chanock RM: Respiratory syncytial virus. In: Fields' Virology (3rd edition). BN Fields, DM Knipe, PM Howley (Eds.), Lippincott-Raven, Phildadelphia, USA (1996):1313-1351.
2. Hall CB, Walsh EE, Schnabel KC et al.: Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J. Infect. Dis. (1990) 162:1283-1290.
3. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ: Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA (1999) 282:1440-1446
4. Langley JM, Wang EEL, Law BJ et al.: Economic evaluation of respiratory syncytial virus infections in Canadian children: a Pediatric Investigative Network on Infections in Canada (PICNIC) study. J. Pediatr. (1997) 131:113-117.
5. Hall WJ, Hall CB, Speers DM: Respiratory syncytial virus infections in adults: clinical, virologic and serial pulmonary function studies. Ann. Intern. Med. (1978) 88:203-205.
6. Hall CB, Douglas RG JR: Modes of transmission of respiratory syncytial virus. J. Pediatr. (1981) 99:100-103.
7. Martinez FD, Wright AL, Taussig LM et al.: Asthma and wheezing in the first six years of life. N. Engl. J. Med. (1995) 332:133-138.
8. Kattan M: Epidemiologic evidence of increased airway reactivity in children with a history of bronchiolitis. J. Pediatr. (1999) 135:8-13.
9. Sigurs N: Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am. J. Crit. Care Med.(2000) 61:1501-1507.
10. Welliver RC: Chemokines, cytokines and inflammatory cells in respiratory syncytial virus infections: similarities to allergic responses. Pediatr. Asthma Allergy Immunol. (2000) 14:93-100.
11. Piedmonte G, King KA, Holmgren NL, Bertrand PJ, Rodriguez MM, Hirsch RL: A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammations in rat airways. Pediatr. Res. (2000) 47:351-356.
12. Fergie JE: effects of ribavirin therapy on RSV infections in high-risk infants and young children 2 years after hospitalization. In: RSV and asthma: Is there a link? PW Hiatt (Ed.), American Thoracic Society, New York, USA (1998):43-45.
13. Edell DS, Bruce E, Hale K, Khoshoo V: Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus with ribavirin in previous healthy infants: a preliminary report. Pediatr. Pulmonol. (1998) 25:154-158.
14. Rodriguez WJ, Arrobio J, Fink R et al.: Prospective follow-up and pulmonary functions from a placebo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis. Arch. Pediatr. Adol. Med. (1999) 153:469-474.
15. Krilov LR, Mandel FS, Barone SR et al.: Follow-up of children with respiratory syncytial virus lower respiratory tract infection in 1986 and 1987: Potential effect of ribavirin on long-term pulmonary function. Pediatr. Infect. Dis. J. (1997) 16:273-276.
16. Long CE, Voter KZ, Barker WH, Hall CB: Long-term follow-up of children hospitalized with respiratory syncytial virus lower respiratory infection and randomly treated with ribavirin or placebo. Pediatr. Infect. Dis. J. (1997) 16:1023-1028.
17. Meissner CH, Welliver RC, Chartrand SA et al.: Immunoptophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr. Infect. Dis. J. (1999) 18:223-231
18. Falsey AR, Cunningham CK, Barker WH et al.: Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. (1995) 172:389-394.
19. Whimley E, Ghosh S: Respiratory syncytial virus infections in immunocompromised adults. Curr. Clin. Top. Infect. Dis. (2000) 20:232-255.
20. Sable CA, Hayden FG: Orthomyxoviral and paramyxoviral infections in transplant patients. Infect. Dis. Clin. North Amer. (1995) 9:987-1003.
21. Dowell SF, Anderson LJ, Gary HE JR et al.: Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. (1996) 174:456-462.
22. Oglivie MM, Vatheneo S, Radford M et al.: Maternal antibody and respiratory syncytial virus infection in infancy. J. Med. Virol. (1981) 7:263-271.
23. Prince GA, Horswood RL, Camargo E, Koenig D, Chanock RM: Mechanisms of immunity to respiratory syncytial virus in cotton rats. J. Immunol. (1979) 42:81-87.
24. Prince GA, Horswood RL, Chanock RM: Quantitative aspects of passive immunity to respiratory syncytial infection in infant cotton rats. J. Virol. (1985) 55:515-520.
25. Prince GA, Hemming VG, Horswood RL, Chanock RM: Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res. (1985) 3:193-206.
26. Suffin SC, Prince GA, Muck KB, Porter DD: Immunoprophylaxis of respiratory syncytial virus infection in the infant ferret. J. Immunol. (1979) 123:10-14.
27. Weltzin R: The therapeutic potential of monoclonal antibodies against respiratory syncytial virus. Expert Opin. Investig. Drugs (1998) 7:1271-1283.
28. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL: Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group and maternal antibody level. J. Pediatr. (1981) 98:708-715.
29. Groothuis JR, Levin MJ, Rodriguez W et al.: Intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. Antimicrob. Agents Chemother. (1991) 35:1469-1473.
30. Meissner HC, Fulton DR, Groothuis JR et al.: Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob. Agents Chemother. (1993) 37:1655-1658.
31. Siber GR, Leszcynski J, Pena-Cruz et al.: Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J. Infect. Dis. (1992) 165:456-463.
32. Groothuis JR, Simoes EAF, Levin MJ et al.: Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. New EngL J. Med. (1993) 329:1524-1530.
33. Groothuis JR, Simoes EAF, Hemming VG: Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics (1995) 95:463-467.
34. The Prevent Study Group: Reduction of respiratory syncytial virus hospitalization among premature infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics (1997) 99:93-99
35. Simoes EAF, Groothuis JR, Tristam DA et al.: Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J. Pediatr. (1996) 129:214-219.
36. Simoes EAF, Sondheimer HM, Top FH JR: Respiratory syncytial immune globulin for prophylaxis against respiratory syncytial disease in infants and children with congenital heart disease: The cardiac study group. J. Pediatr. (1998) 133:492-499.
37. American Academy Of Pediatrics: Respiratory syncytial virus. In: 2000 Red Book: Report of the Committee on Infectious Diseases, 25th Edition. Pickering LK (Ed.), Elk Grove Village, Il, USA (2000):483-487.
38. Walsh EE, Hruska J: Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J. Virol. (1985) 47:171-177.
39. Cote PJ, Fernie Be Ford EC, Shih JW, Gerin JL: Monoclonal antibodies to respiratory syncytial virus: detection of virus neutralization and other antigen-antibody systems using infected human and murine cells. J. Viro. Methods (1981) 3:137-147.
40. Taylor G, Stott EJ, Bew M et al.: Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology (1984) 52:137-142.
41. Anderson LJ, Hierholzer JC, Tsou C et al.: Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J. Infect. Dis. (1985) 151:626-633.
42. Anderson LJ, Hierholzer JC, Stone YO, Tsou C, Bernie BF: Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay. J. Clin. Microbiol (1986) 23:475-480.
43. West WHI, Lounsbach GR, Bourgeois et al.: Biological activity of, binding site and affinity of monoclonal antibodies to the fusion protein of respiratory syncytial virus. J. Gen. Virol. (1994) 75:2813-2819.
44. Anderson LJ, Bingham P, Hierholzer JC: Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J. Virol. (1988) 62:4232-4238.
45. Walsh EE, Schlesinger JJ, Brandriss MW: Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect. Immun. (1984) 43:756-758.
46. Johnson S, Griego SD, Pfarr DS et al.: A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19. J. Infect. Dis. (1999) 180:35-40.
47. Sanchez P: Immunoprophylaxis for respiratory syncytial virus. Pediatr. Infect. Dis. J. (2000) 21:473-478.
48. The Impact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics (1998) 102:531-537
49. Simoes EA, Groothuis JR: Respiratory syncytial virus prophylaxis-the story so far. Respiratory Med. (2002) 96 (Suppl. B):S15-24.
50. Sorrentino M, Powers T, The Palivizumab Study Group: Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. Pediatr Infect. Dis. J. (2000) 19:1068-1071.
51. Cohen AH, Sorrentino MS, Powers T: Effectiveness of palivizumab for preventing serious RSV disease. J. Respir. Dis. For Pediatricians (2000) 2 (4):S30-S32.
52. The Synagis Outcomes Registry Study Group: Palivizumab prophylaxis of respiratory syncytial virus (RSV)-results from the 2000-2001 Synagis outcomes registry. Pediatr. Infect. Dis. J. (2002) in press
53. Joffe S, Ray GT, Escobar GJ, Balck S, Lieu TA: Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics (1999) 104:419-427.
54. Groothuis JR: The pitfalls of using managed care databases in cost-effectiveness research. Pediatrics (1999) 104:1124-1125.
55. Marchetti A, Lau H, Lagar R, Wang L, Devercelli G: Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin. Therapeutics (1999) 21:752-766.
56. Hall CB: Respiratory syncytial virus and parainfluenza virus. New Engl. J. Med. (2001) 344:1917-1928.
57. Malley R, Devincenzo J, Ramilo O et al.: Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. (1998) 178:1555-1561.
58. Englund JA, Piedra PA, Whimbey E: Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am. J. Med. (1997) 102:61-70.
59. Devincenzo JP, Hirsch RL, Fuentes RJ, Top FH JR: Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation-a compassionate use experience. Bone Marrow Transplant. (2000) 25:161-165.
60. Prince GA, Matthews, Curtis SJ, Porter DD: Treatment of respiratory syncytial virus bronchiolits and pneumonia in a cotton rat model with systemically administered monoclonal antibody (palivizumab) and glucocorticosteroid. J. Infect. Dis. (2000) 182:1326-1330.
61. Krilov LR: Recent developments in the treatment and prevention of respiratory syncytial virus infection. Expert Opin. Ther. Patents (2002) 12:441-449.